Enhertu #11 today…but no blood return on my port. Waiting for the Alteplase (aka draino) to work before they can start the infusion. 🤷🏻‍♀️

AstraZeneca profit rose in the 1st quarter, buoyed by demand for its cancer blockbusters Imfinzi and Tagrisso as well as newcomer Enhertu.

Revenue surged 17% last quarter.

Don't question you know what just look over there as Putin very bad man, more climate change...

$AZN Oncology segment, drugmaker's top business, delivered a 26% jump in Q1 sales to $5.11B; Enhertu [breast cancer therapy] and Tezspire [asthma] jumped 59% in the quarter.

Enhertu凄すぎる。
IHC0に対しても効いてしまうとなると、感度の高いHER2マーカーの開発が急務では？話を聞いたことがあるけど、はたしてどうなるやら

📢 Support Breast Cancer Now in urgently highlighting the issue of the #EnhertuEmergency for those with HER2-low breast cancer. Sign & share their petition to make Enhertu accessible on the NHS: bit.ly/3xGfAdI

ついに来ました！HER2-lowにおける1st lineの標準治療が変わります。DESTINY-Breast06試験: ホルモン受容体陽性HER2低発現の転移再発乳癌の1次治療において、T-DXd(エンハーツ)が従来の標準治療と比べて統計学的に有意なPFS延長を認めたとのこと。businesswire.com/news/home/2024…

$AZN--

Breakout today!!
Results from a phase 3 trial showed that treatment with AstraZeneca's Enhertu led to statistically significant improvement in progression-free survival compared to chemotherapy in patients with HR-positive, HER2-low metastatic breast cancer...

$AZN ++ the story continues to positive—-Another win for ENHERTU 💥💥💥

Andrewdc208 #AZN Truqap + Faslodex rec approval in EU, +ve Enhertu
#DGI9 $25m Verne received
#EYE Tesco contract
#I3E FY23 ptp $20.9m (FY22 $55.8m)
#JSE FY23 LOSS $91.3m
#OMIP FY23 Op pr £0.5m (22 £0.9m)
#SRB FY23 prod 33.1koz (22 31.9koz)
#SUPR €75.3m acq France
#YCA NAV £6.88 -3.2% qoq

#HER2 is getting far more than just #BreastCancer
Are we witnessing a breakthrough in treating #HER2 #brain #metastases with novel antibody drug conjugates like #Enhertu ??
The whole story of #Enhertu #ADCs #HER2 incl #HER2 low #HER2 ultralow is getting far more interesting 👆…

🎧Learn about FDA’s recent oncology treatment approval of Enhertu (fam-trastuzumab deruxtecan-nxki) in the latest #FDADISCO podcast: fda.gov/media/178029/d…

TAM fo Enhertu

With the current rate of progress for Enhertu the HER2+ specification might end up just being removed.

The finding from DB-06 will result in early usage of Enhertu (T-DXd), basically soon after the endocrine therapy, and not more low HER2 as selection, it will be a matter of not being HER2 negative to receiving the treatment (double negative expression, :) )

Another Enhertu win for $DSNKY $AZN

daiichisankyo.us/press-releases…

Enhertu is rewriting the rules of breast cancer diagnosis and treatment.

Positive Phase III data for Enhertu in breast cancer thepharmaletter.com/article/positi…

~450k eligible pts by 2027 for Enhertu, Dato, HER3-Dxd

I've joined with Breast Cancer Now to call on NICE, NHS England, AstraZenecaUK and Daiichi Sankyo UK to make the life-extending drug, Enhertu available on the NHS. Will you join me? Sign the petition #EnhertuEmergency action.breastcancernow.org/enhertu-emerge…

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial - businesswire.com/news/home/2024…